Press Release February 21, 2023 Post-harvest Treatment Market worth $2.7 billion by 2028, at a CAGR of 7.8%
Press Release February 21, 2023 Hot Flashes Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Press Release February 21, 2023 Hyperphosphatemia Market to Advance at Moderate CAGR During the Forecast Period (2022-2032) – Estimates DelveInsight | Key Companies – PUMC Pharma, Ardelyx, Daiichi Sankyo, Shield Therapeutics
Press Release February 21, 2023 Severe Hypoglycemia Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Press Release February 21, 2023 Sepsis Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Press Release February 21, 2023 ESR1 Mutated Metastatic Breast Cancer Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Radius Pharmaceuticals/ Menarini Group
Press Release February 21, 2023 Anemia in Chronic Kidney Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Akebia Therapeutics
Press Release February 21, 2023 Alzheimer’s Disease Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies – Eisai/BioArcticAB, Alzheon, Hoffmann-La Roche
Press Release February 21, 2023 Type 2 Diabetes Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Press Release February 21, 2023 Mantle Cell Lymphoma Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Eli Lilly and Company, Oncternal Therapeutics, Novalgen